Health and Lifestyle for the over 50s

New Drugs May Reduce Chances of Heart Attack or Stroke

Posted by The Best of Health
Categories: Health and Wellbeing / Heart Related /

Drug trialTreatments for high cholesterol, and related problems such as heart attack or stroke, are constantly being refined. New drugs have been trialed in the US which lower cholesterol and have been shown to reduce the risk of these problems occurring significantly, compared to treatment with conventional drugs such as statins.

The Trial

In safety and efficacy trials funded by drug manufacturer Amgen, 4,465 patients were selected at random to either receive the drug evolocumab alongside their standard care, or to receive only standard care involving a prescription of statins.

After one year, the rate of cardiovascular events – including heart attack, stroke, hospitalisation, surgery to open blocked arteries, and death – was shown to be 0.95% in the evolocumab group, compared to 2.18% in the group taking traditional statins.

“The reduction in LDL was profound and that may be why we saw a marked reduction in cardiovascular events so quickly,” said lead author Marc Sabatine, senior physician in the Division of Cardiovascular Medicine at Brigham and Women’s Hospital in Boston.

“It suggests that if we can drive a patient’s LDL cholesterol down a large amount to a very low level, we may start to see a benefit sooner than would be expected with a more modest intervention.”

The research was published in the New England Journal of Medicine, and presented at the American College of Cardiology annual conference in San Diego.

How the Drug Works

Evolocumab is part of a new class of drugs called PCSK9 inhibitors, which work differently from statins.

It is a human monoclonal antibody, which blocks the harmful protein PCSK9, stopping it from interfering with the liver’s capacity to remove cholesterol from the blood. As the liver can work better, this in turn lowers the blood’s levels of low-density lipoprotein, otherwise known as LDL or ‘bad cholesterol.’

Past research has shown evolocumab to lower LDL cholesterol by up to 61%

Potential Side Effects

At this stage, there is still some concern about potential side effects to these drugs, including concerns about their effect on thinking, memory and confusion.

Whilst these problems only affected 1-2% of patients, and may be temporary, they were twice as common as this among patients taking another of the new class of drugs. This will be monitored closely as trials on these drugs continue.

Future Availability

These drugs could be available in the US as soon as later this year, if they are approved following a review of the data by the FDA.

However, more years of study are planned to fully understand their effects. For instance, the figures from this initial study are uncertain, since the overall number of cardiovascular events was small – only 60 altogether. A long term study of 27,000 people planned for 2017 should give a more reliable and broader picture of the comparative effectiveness of these drugs.

If it is proven that they are significantly more effective than existing drugs, then this could provide a welcome alternative for those people who do not succeed in lowering their high cholesterol with diet, exercise, and the conventional statin drugs currently available.

One independent expert, Dr Judith Hochman of NYU Langone Medical Center, described these results as “really impressive and very encouraging.”

Related Posts

Posted by The Best of Health

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies allow us to count visits and traffic sources, so we can measure and improve the performance of our site.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie

We use Google Tag Manager to monitor our traffic and to help us AB test new features.

Decline all Services
Accept all Services